Comments
Glenmark Pharmaceuticals has received final approval from the US health regulator for generic version of Rythmol SR capsules, an anti-arrhythmic medication, which treats illnesses associated with rapid heart beats.
“Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (US FDA) for Propafenone Hydrochloride extended-release capsules USP, 225 mg, 325 mg, and 425 mg,” Glenmark Pharmaceuticals said in a BSE filing today.
Propafenone Hydrochloride extended-release capsules is a generic version of GlaxoSmithKline, LLC’s Rythmol Capsules.
According to IMS Health sales data for the 12 months to July 2017, Rythmol SR capsules achieved annual sales of approximately $69.2 million, Glenmark said.
The company’s current portfolio consists of 123 products authorised for distribution in the US marketplace and 63 Abbreviated New Drug Applications (ANDA) pending approval with USFDA.
Glenmark Pharmaceuticals’ shares were trading at Rs 578 on the BSE, down 0.47 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.